Supplements That Help With Gallbladder Disease on Ozempic (Semaglutide)
At a glance
- Ozempic label / Acute gallbladder disease is listed under warnings and precautions [1]
- Label action / Gallbladder studies if cholelithiasis or cholecystitis are suspected [1]
- Ozempic indication / Type 2 diabetes; no weight-loss indication [1]
- GLP-1 class risk / Gallbladder disorders 26% more common than with control across 21 trials and 99,599 patients [2]
- SELECT, semaglutide 2.4 mg / Gallbladder-related disorders 2.8% vs 2.3% on placebo [3]
The direct answer
No study of vitamin C, soluble fiber, omega-3 fatty acids, magnesium, lecithin or any other supplement for gallbladder disease in people taking semaglutide was identified, and the Ozempic label names no supplement.
The label's gallbladder entry is a diagnostic instruction: when cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1].
What the Ozempic label says
Ozempic injection is approved to improve blood sugar in adults with type 2 diabetes, to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [1]. Ozempic has no weight-loss indication [1].
Under warnings and precautions, the label lists acute gallbladder disease, and the action it gives is gallbladder studies if cholelithiasis or cholecystitis are suspected [1]. Cholecystitis and cholecystectomy also appear in the label's postmarketing reports, where frequency cannot be estimated [1].
How often gallbladder problems occur
A 2025 meta-analysis of 21 randomized trials covering 99,599 patients found gallbladder disorders 26% more common with GLP-1 receptor agonists than with control [2]. The SELECT trial used semaglutide 2.4 mg, above Ozempic's 2 mg maximum [1], in adults with established cardiovascular disease and overweight or obesity. It reported gallbladder-related disorders in 2.8% vs 2.3% on placebo, mainly cholelithiasis at 1.4% vs 1.1%; cholecystitis was 0.6% in both groups [3].
Frequently asked questions
What does the Ozempic label say to do if gallbladder disease is suspected?
Are gallbladder problems more common on semaglutide?
References
- U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
- Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025;86(20):1805-1819. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
- Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring). 2025;33(3):452-462. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial